Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 96
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Aging (Albany NY) ; 13(22): 24511-24523, 2021 11 24.
Article in English | MEDLINE | ID: mdl-34818212

ABSTRACT

INTRODUCTION: Aging is characterized by the progressive loss of physiological capacity. Changes in gene expression can alter activity in defined age-related molecular pathways leading to cellular aging and increased aging disease susceptibility. The aim of the current study was to evaluate whether hyperbaric oxygen therapy (HBOT) affects gene expression in normal, non-pathological, aging adults. METHODS: Thirty-five healthy independently living adults, aged 64 and older, were enrolled to receive 60 daily HBOT exposures. Whole blood samples were collected at baseline, at the 30th and 60th HBOT session, and 1-2 weeks following the last session. Differential gene expression analysis was performed. RESULTS: Following 60 sessions of HBOT, 1342 genes and 570 genes were differently up- and downregulated (1912 total), respectively (p < 0.01 FDR), compared to baseline. Out of which, five genes were downregulated with a >1.5-fold change: ABCA13 (FC = -2.28), DNAJ6 (FC = -2.16), HBG2 (FC = -1.56), PDXDC1 (FC = -1.53), RANBP17 (FC = -1.75). Two weeks post-HBOT, ABCA13 expression was significantly downregulated with a >1.5fold change (FC = -1.54, p = 0.008). In conclusion, for the first time in humans, the study provides direct evidence of HBOT is associated with transcriptome changes in whole-blood samples. Our results demonstrate significant changes in gene expression of normal aging population.


Subject(s)
Aging , Hyperbaric Oxygenation , Transcriptome/drug effects , Aging/genetics , Aging/metabolism , Humans , Oxygen/pharmacology , RNA, Messenger/blood , RNA, Messenger/genetics , Transcriptome/genetics
2.
J Int Soc Sports Nutr ; 18(1): 19, 2021 Mar 02.
Article in English | MEDLINE | ID: mdl-33653365

ABSTRACT

BACKGROUND: In this study, we investigated the effects of supplementation and exercise on the expression of genes associated with inflammation like CCL2, CRP, IL1, IL6, IL10 mRNA in elderly women. METHODS: Twenty four participants divided randomly into two groups were subjected to 6 weeks of the same health training program (three times per week). SUP group (supplemented, n = 12, mean age 72.8 ± 5.26 years and mean body mass 68.1 ± 8.3 kg) received 1000 mg of Vitamin C/day during the training period, while CON group (control, n = 12, mean age 72.4 ± 5.5 years and body mass 67.7 ± 7.5 kg) received placebo. RESULTS: No significant changes in IL-1, IL-6, IL-10 and CRP mRNA were observed within and between groups. However, there was a clear tendency of a decrease in IL-6 (two-way ANOVA, significant between investigated time points) and an increase in IL-10 mRNA noted in the supplemented group. A significant decrease in CCL2 mRNA was observed only in the CON group (from 2^0.2 to 2^0.1, p = 0.01). CONCLUSIONS: It can be concluded, that 6 weeks of supplementation and exercise was too short to obtain significant changes in gene expression in leukocytes, but supplementation of 1000 mg vitamin C positively affected IL-6 and IL-10 expression - which are key changes in the adaptation to training. However, changes in body mass, IL1 and CCL2 were positive in CON group. It is possible that Vitamin C during 6 weeks of supplementation could have different effects on the expression of individual genes involved in the immune response. TRIAL REGISTRATION: Retrospectively registered.


Subject(s)
Ascorbic Acid/administration & dosage , Gene Expression , Immunity/genetics , Physical Conditioning, Human/physiology , Vitamins/administration & dosage , Aged , Ascorbic Acid/blood , Body Composition , Body Mass Index , Chemokine CCL2/blood , Chemokine CCL2/genetics , Female , Humans , Interleukin-1/blood , Interleukin-1/genetics , Interleukin-10/blood , Interleukin-10/genetics , Interleukin-6/blood , Interleukin-6/genetics , Oxidative Stress , Oxygen Consumption , RNA, Messenger/blood , Receptors, Immunologic/blood , Receptors, Immunologic/genetics , Time Factors , Vitamins/blood
3.
Clin Exp Nephrol ; 25(5): 522-530, 2021 May.
Article in English | MEDLINE | ID: mdl-33548016

ABSTRACT

BACKGROUND: Chronic kidney disease (CKD) is a disorder that affects millions worldwide, and current treatment options aiming at inhibiting the progression of kidney damage are limited. Long noncoding RNA (lncRNA) H19 is one of the first explored lncRNAs and its deregulation is associated with renal pathologies, such as renal cell injury and nephrotic syndrome. However, there is still no research investigating the connection between serum lncRNA H19 expressions and clinical outcomes in CKD patients. Therefore, we investigated the relation of serum lncRNA H19 expressions with routine biochemical parameters, inflammatory cytokines, oxidative stress and mineralization markers in advanced CKD patients. METHODS: lncRNA H19 serum levels from 56 CKD patients and 20 healthy controls were analyzed with reverse-transcription quantitative polymerase chain reaction method. Serum tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), and osteocalcin (OC) levels were measured with enzyme linked-immunosorbent assay. Total antioxidant status (TAS) and total oxidative status (TOS) levels were evaluated by the routine measurement method. RESULTS: We found that lncRNA H19 expressions were upregulated in patients with CKD compared to the controls. Furthermore, lncRNA H19 relative expression levels showed a negative relationship with glomerular filtration rate (GFR) while it was positively correlated with ferritin, phosphorus, parathyroid hormone, TNF-α, IL-6, OC, TAS and TOS levels. CONCLUSION: lncRNA H19 expressions were increased in CKD stage 3-5 and HD patients, and elevated lncRNA H19 expressions were associated with decreased glomerular filtration rate, inflammation, and mineralization markers in these patients.


Subject(s)
Interleukin-6/blood , Osteocalcin/blood , RNA, Long Noncoding/blood , Renal Insufficiency, Chronic/blood , Tumor Necrosis Factor-alpha/blood , Adult , Aged , Biomarkers/blood , C-Reactive Protein/metabolism , Case-Control Studies , Female , Ferritins/blood , Glomerular Filtration Rate , Humans , Inflammation/blood , Male , Middle Aged , Oxidative Stress/physiology , Parathyroid Hormone/blood , Phosphorus/blood , RNA, Messenger/blood , Renal Insufficiency, Chronic/physiopathology , Up-Regulation
4.
Sci Rep ; 10(1): 21857, 2020 12 14.
Article in English | MEDLINE | ID: mdl-33318568

ABSTRACT

Using genome-wide transcriptome analysis by RNA sequencing of first trimester plasma RNA, we tested whether the identification of pregnancies at risk of developing pre-eclampsia with or without preterm birth or growth restriction is possible between weeks 9-14, prior to the appearance of clinical symptoms. We implemented a metaheuristic approach in the self-learning SVM algorithm for differential gene expression analysis of normal pregnancies (n = 108), affected pregnancies (n = 34) and non-pregnant controls (n = 19). Presymptomatic candidate markers for affected pregnancies were validated by RT-qPCR in first trimester samples (n = 34) from an independent cohort. PRKG1 was significantly downregulated in a subset of pregnancies with birth weights below the 10thpercentile as shared symptom. The NRIP1/ZEB2 ratio was found to be upregulated in pregnancies with pre-eclampsia or trisomy 21. Complementary quantitative analysis of both the linear and circular forms of NRIP1 permitted discrimination between pre-eclampsia and trisomy 21. Pre-eclamptic pregnancies showed an increase in linear NRIP1 compared to circular NRIP1, while trisomy 21 pregnancies did not.


Subject(s)
Nuclear Receptor Interacting Protein 1/blood , Pre-Eclampsia/blood , RNA, Messenger/blood , Up-Regulation , Zinc Finger E-box Binding Homeobox 2/blood , Adult , Biomarkers/blood , Female , Humans , Pregnancy , Prospective Studies
5.
Aging (Albany NY) ; 12(8): 6630-6643, 2020 04 16.
Article in English | MEDLINE | ID: mdl-32302289

ABSTRACT

Osteoarthritis (OA) a disease associated with joints and become severe with age, due to softening, inflammation and degradation of cartilage in joints. The agents that can target OA is needed, specifically without any side effects. Garcinia mangostana L. (Mangosteen) a tropical fruit used to treat many skin and stomach associated ailments. γ- Mangostin (γ-MS) a key bioactive substance present in mangosteen. Here, we aimed to explore γ-MS potential in targeting the pro-inflammatory cytokine, factors and miRs in OA progression. Significantly, γ-MS suppresses the inflammatory cytokines (IL-6, TNF-α, and INF- γ) and factors (NF-κB, STAT3, and COX-2) which regulates/participate in the catabolic process of cartilage destruction. Result of Hematoxylin-eosin (H&E) staining of tissue sections of OA joints of γ-MS treated and non-treated mice confirm γ-MS improves the signs of injuries, and maintains the structural integrity of the articular cartilage (epiphyseal disk joints and bone marrow) and reduces inflammation. Mechanistically, γ-MS targets miR-98-5p and miR-124-3p which are found to suppress the expression IL-6 and NF-κB, respectively. But in OA these miRs are inhibited, especially miR-124-3p which regulates not only NF-κB but also TNF-α, IL-6 and MMP7. With a further investigation underway, γ-MS represents an important source for treating and managing OA.


Subject(s)
Gene Expression/drug effects , Osteoarthritis/drug therapy , Phytotherapy , Signal Transduction/drug effects , Xanthones/therapeutic use , Animals , Cartilage, Articular/pathology , Cell Line , Cyclooxygenase 2/metabolism , Disease Models, Animal , Fibroblasts , Garcinia mangostana , Humans , Interferon-gamma/genetics , Interleukin-6/genetics , Interleukin-6/metabolism , Mice , MicroRNAs/metabolism , NF-kappa B/genetics , NF-kappa B/metabolism , Osteoarthritis/blood , Osteoarthritis/chemically induced , Osteoarthritis/pathology , Papain , Plant Preparations , RNA, Messenger/blood , STAT3 Transcription Factor/metabolism , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , Xanthones/pharmacology
6.
Clin Nutr ; 39(10): 3175-3181, 2020 10.
Article in English | MEDLINE | ID: mdl-32111521

ABSTRACT

BACKGROUND & AIMS: Although the mechanisms by which statins promote muscle disorders remain unclear, supplementation with dietary antioxidants may mitigate statins' side effects. This study aimed to investigate whether the consumption of Brazil nuts modulates serum creatine kinase (CK) activity in patients regularly using statins. METHODS: The study was performed in the Ribeirão Preto Medical School University Hospital. Thirty-two patients in regular use of statins were divided according to CK activity levels (G1: increased or G2: normal) and received one unit of Brazil nut daily for 3 months. Body composition, blood selenium (Se) concentrations, erythrocyte glutathione peroxidase (GPX) activity, oxidative stress parameters, and CK activity were evaluated before and after supplementation. RESULTS: In both groups, supplementation with one Brazil nut daily for 3 months contributed to achieve decreased levels of CK activity in serum, with positive changes in plasma and erythrocyte Se concentrations (p < 0.0001), and increased levels of GPX activity. Among the parameters related to curbing of oxidative stress, we observed reduced levels of malondialdehyde (MDA) and superoxide dismutase (SOD) in both groups after supplementation. We also found a moderately negative association between CK and GPX activity (r = -41; p < 0.02). Expression of selenoproteins GPX1, SELENOP, and SELENON after Brazil nut supplementation was unchanged. CONCLUSION: Brazil nut consumption enhanced the control of CK activity by improving oxidative stress biomarkers in patients using statins but did not modulate mRNA expression of selenoproteins.


Subject(s)
Bertholletia , Creatine Kinase/blood , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Nuts , Oxidative Stress/drug effects , RNA, Messenger/genetics , Selenoproteins/genetics , Adolescent , Adult , Biomarkers/blood , Brazil , Female , Gene Expression Regulation , Glutathione Peroxidase/blood , Glutathione Peroxidase/genetics , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Male , Middle Aged , Muscle Proteins/blood , Muscle Proteins/genetics , RNA, Messenger/blood , Selenoprotein P/blood , Selenoprotein P/genetics , Selenoproteins/blood , Time Factors , Young Adult , Glutathione Peroxidase GPX1
7.
Sci Rep ; 9(1): 20208, 2019 12 27.
Article in English | MEDLINE | ID: mdl-31882899

ABSTRACT

Progress in the preclinical and clinical development of neuroprotective and antiepileptogenic treatments for traumatic brain injury (TBI) necessitates the discovery of prognostic biomarkers for post-injury outcome. Our previous mRNA-seq data revealed a 1.8-2.5 fold increase in clusterin mRNA expression in lesioned brain areas in rats with lateral fluid-percussion injury (FPI)-induced TBI. On this basis, we hypothesized that TBI leads to increases in the brain levels of clusterin protein, and consequently, increased plasma clusterin levels. For evaluation, we induced TBI in adult male Sprague-Dawley rats (n = 80) by lateral FPI. We validated our mRNA-seq findings with RT-qPCR, confirming increased clusterin mRNA levels in the perilesional cortex (FC 3.3, p < 0.01) and ipsilateral thalamus (FC 2.4, p < 0.05) at 3 months post-TBI. Immunohistochemistry revealed a marked increase in extracellular clusterin protein expression in the perilesional cortex and ipsilateral hippocampus (7d to 1 month post-TBI), and ipsilateral thalamus (14d to 12 months post-TBI). In the thalamus, punctate immunoreactivity was most intense around activated microglia and mitochondria. Enzyme-linked immunoassays indicated that an acute 15% reduction, rather than an increase in plasma clusterin levels differentiated animals with TBI from sham-operated controls (AUC 0.851, p < 0.05). Our findings suggest that plasma clusterin is a candidate biomarker for acute TBI diagnosis.


Subject(s)
Biomarkers/metabolism , Brain Injuries, Traumatic/metabolism , Brain/metabolism , Clusterin/metabolism , RNA, Messenger/metabolism , Animals , Biomarkers/blood , Brain Injuries, Traumatic/blood , Brain Injuries, Traumatic/genetics , Cerebral Cortex/metabolism , Clusterin/blood , Clusterin/genetics , Hippocampus/metabolism , Immunohistochemistry/methods , Kinetics , Male , RNA, Messenger/blood , RNA, Messenger/genetics , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction/methods , Thalamus/metabolism , Time Factors
8.
Anal Bioanal Chem ; 411(1): 139-146, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30374725

ABSTRACT

A novel electrochemical luminescence (ECL) aptamer biosensor via polymerase amplification is constructed for label-free detection of leukemia marker mRNA (miR-16). In order to achieve the ultrasensitive detection of the target mRNA, the cyclic target chain displacement polymerization of leukemia marker mRNA assisted with Klenow fragment of DNA polymerase is employed. The determination is carried out by recording the ECL emission of pyridine ruthenium (Ru(bpy)32+) complexes embedded into the assistance DNA (ADNA) loaded on the nanogold surface, after the hybridization reaction between the probe DNA (PDNA) and the remaining sequence of the CP's stem part, and the formation of a core-shell sun-like structure. The mercapto-modified capture DNA (CP) is immobilized on the surface of a magneto-controlled glassy carbon electrode by Au-S bond. The CP is opened and hybridized with the target mRNA to form double-stranded DNA. In the presence of polymerase, primer DNA, and bases (dNTPs), the primer chain gets access to its complementary sequence of the stem part and then triggers a polymerization of the DNA strand, leading to the release of mRNA and starting the next polymerization cycle. Finally, the composite of PDNA-covered and ADNA-covered (embedded with Ru(bpy)32+) gold nanoparticles (hereafter called AuNPs@(PDNA+ADNA-Ru(bpy)32+) is added, and the ECL intensity is recorded. Because of the polymerization cycle and the aggregation of the illuminator of Ru(bpy)32+, the detected signal is amplified significantly. The results showed that the corresponding ECL signal has a good linear relationship with a logarithm of target mRNA concentration in the range of 1 × 10-16 to 1 × 10-7 mol/L, with a detection limit of 4.3 × 10-17 mol/L. The mRNA spiked in the human serum sample is determined, and the recoveries are from 97.2 to 102.0%. This sensor demonstrates good selectivity, stability, and reproducibility. Graphical abstract ᅟ.


Subject(s)
Aptamers, Nucleotide/metabolism , Biomarkers, Tumor/blood , Biosensing Techniques/methods , DNA-Directed DNA Polymerase/metabolism , Electrochemical Techniques/methods , Leukemia/blood , MicroRNAs/blood , RNA, Messenger/blood , Calibration , DNA Probes , Electrochemical Techniques/standards , Electrodes , Ferrosoferric Oxide/chemistry , Gold/chemistry , Humans , Limit of Detection , Luminescence , Metal Nanoparticles/chemistry , Reproducibility of Results
9.
Nan Fang Yi Ke Da Xue Xue Bao ; 38(11): 1277-1287, 2018 Nov 30.
Article in Chinese | MEDLINE | ID: mdl-30514673

ABSTRACT

OBJECTIVE: To investigate the effects of sera from rats fed with Huganqingzhi tablets (HGT) on endoplasmic reticulum (ER) stress in a steatotic hepatocyte model of free fatty acids (FFAs)-induced nonalcoholic fatty liver disease (NAFLD) and explore the possible mechanism. METHODS: FFAs prepared by mixing oleic acid and palmitic acid at the ratio of 2:1. HepG2 cells were treated with the sera from rats fed with low-, moderate-or high-dose HGT (HGT sera) or sera of rats fed with fenofibrate (fenofibrate sera), followed by treatment with 1 mmol/L FFAs for 24 h to induce hepatic steatosis. Oil red O staining was used to observe the distribution of lipid droplets in the cells. The biochemical parameters including triglyceride (TG), lactated hydrogenase (LDH), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured using a commercial kit. The morphological changes of the ER in the cells were observed using transmission electron microscopy. The protein/mRNA expressions of ER stress-related signal molecules including GRP78, PERK, p-PERK, ATF6, ATF4, CASPASE-12, CHOP, XBP-1, PKC, and p-PKC-δ were detected using Western blotting and/or quantitative real-time PCR (qRT-PCR). The changes in the protein expressions of GRP78, p-PERK, CASPASE-12 and CHOP were also detected in cells with transient transfection of PKC-δ siRNA for PKC-δ knockdown. RESULTS: Compared with the control cells, the cells treated with FFAs showed significantly increased levels of TG, AST, and ALT (P < 0.05). Compared with FFAs-treated cells, the cells pretreated with HGT sera or fenofibrate sera all showed significantly decreased TG, AST and ALT levels (P < 0.05), reduced accumulation of the lipid droplets (P < 0.05), and lowered protein or mRNA expression levels of GRP78, p-PERK, ATF6, ATF4, CHOP, CASPASE-12, XBP-1 and p-PKC-δ (P < 0.05). PKC-δ knockdown caused significantly reduced protein expressions of GRP78, p-PERK, CASPASE-12 and CHOP in the cells with FFA-induced hepatic steatosis (P < 0.001); treatment with high-dose HGT serum more significantly reduced the expressions of GRP78 (P < 0.001) and P-PERK (P < 0.01) in FFAs-induced cells with PKC-δ knockdown. CONCLUSIONS: HGT serum can effectively prevent FFAs-induced steatosis in HepG2 cells by alleviating ER stress, in which PKC-δ may act as an important target.


Subject(s)
Drugs, Chinese Herbal/administration & dosage , Endoplasmic Reticulum Stress/drug effects , Non-alcoholic Fatty Liver Disease/prevention & control , Serum , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Disease Models, Animal , Endoplasmic Reticulum/ultrastructure , Endoplasmic Reticulum Chaperone BiP , Fatty Acids, Nonesterified , Fenofibrate/administration & dosage , Hep G2 Cells , Humans , Hypolipidemic Agents/administration & dosage , Microscopy, Electron, Transmission , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/etiology , RNA, Messenger/blood , Rats , Tablets , Triglycerides/blood
10.
Nutrients ; 10(8)2018 Aug 09.
Article in English | MEDLINE | ID: mdl-30096876

ABSTRACT

Norwegians are the second highest consumers of coffee in the world. Lately, several studies have suggested that beneficial health effects are associated with coffee consumption. By analyzing whole-blood derived, microarray based mRNA gene expression data from 958 cancer-free women from the Norwegian Women and Cancer Post-Genome Cohort, we assessed the potential associations between coffee consumption and gene expression profiles and elucidated functional interpretation. Of the 958 women included, 132 were considered low coffee consumers (<1 cup of coffee/day), 422 moderate coffee consumers (1⁻3 cups of coffee/day), and 404 were high coffee consumers (>3 cups of coffee/day). At a false discovery rate <0.05, 139 genes were differentially expressed between high and low consumers of coffee. A subgroup of 298 nonsmoking, low tea consumers was established to isolate the effects of coffee from smoking and potential caffeine containing tea consumption. In this subgroup, 297 genes were found to be differentially expressed between high and low coffee consumers. Results indicate differentially expressed genes between high and low consumers of coffee with functional interpretations pointing towards a possible influence on metabolic pathways and inflammation.


Subject(s)
Coffee , Gene Expression Profiling/methods , Life Style , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , Transcriptome , Adult , Aged , Cross-Sectional Studies , Energy Metabolism/genetics , Female , Gene Expression Regulation , Humans , Inflammation/epidemiology , Inflammation/genetics , Middle Aged , Norway/epidemiology , RNA, Messenger/blood , Risk Factors , Surveys and Questionnaires
11.
J Cell Biochem ; 119(10): 8282-8289, 2018 11.
Article in English | MEDLINE | ID: mdl-29932230

ABSTRACT

Selenoprotein P (SePP) is involved in the protection against diseases. The present study is the first investigation of the effect of selenium supplementation on plasma selenium and expression of SEPP1 in mRNA and protein levels based on metabolic syndrome (MetS), in individuals suffering from coronary artery diseases. In this clinical trial, 160 patients with angiographically documented stenosis of more than 75% in each vessel were enrolled. Patients received either 200-mg selenium yeast tablets or placebo tablets orally after a meal, once daily for 60 days. The mRNA and protein levels of the selenium and SePP1 products were determined before and after the study. From the initial 160 participants, 145 subjects (71 MetS-affected individuals, 74 MetS-unaffected individuals) enrolled in this study. Comparing the selenium and placebo groups, no significant percentage changes of plasma selenium, △Ct SEPP1, or SePP were shown (P > 0.05). Moreover, beyond a significant difference for the expression of SePP in the selenium group compared to its baseline level (P < 0.05), no other significant differences were revealed for plasma selenium and △Ct SEPP1 after the intervention in either group (P > 0.05). Selenium supplementation did not affect plasma selenium or the mRNA or protein level of SePP in either groups after a 2-months intervention beyond a significant increase of SePP in the MetS group. This trial suggests that further studies should investigate the long-term use of selenium supplementation and the effect of a SePP increase on MetS as a potential therapeutic effect.


Subject(s)
Coronary Artery Disease/diet therapy , Dietary Supplements , Metabolic Syndrome/diet therapy , RNA, Messenger/genetics , Selenium/administration & dosage , Selenoprotein P/genetics , Adult , Coronary Angiography , Coronary Artery Disease/blood , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/genetics , Double-Blind Method , Female , Gene Expression Regulation , Humans , Male , Metabolic Syndrome/blood , Metabolic Syndrome/diagnostic imaging , Metabolic Syndrome/genetics , Middle Aged , RNA, Messenger/blood , Selenium/blood , Selenoprotein P/blood
12.
Clin Sci (Lond) ; 131(22): 2707-2719, 2017 Nov 15.
Article in English | MEDLINE | ID: mdl-28982723

ABSTRACT

Abdominal aortic aneurysm (AAA) evolution is unpredictable and no specific treatment exists for AAA, except surgery to prevent aortic rupture. Galectin-3 has been previously associated with CVD, but its potential role in AAA has not been addressed. Galectin-3 levels were increased in the plasma of AAA patients (n=225) compared with the control group (n=100). In addition, galectin-3 concentrations were associated with the need for surgical repair, independently of potential confounding factors. Galectin-3 mRNA and protein expression were increased in human AAA samples compared with healthy aortas. Experimental AAA in mice was induced via aortic elastase perfusion. Mice were treated intravenously with the galectin-3 inhibitor modified citrus pectin (MCP, 10 mg/kg, every other day) or saline. Similar to humans, galectin-3 serum and aortic mRNA levels were also increased in elastase-induced AAA mice compared with control mice. Mice treated with MCP showed decreased aortic dilation, as well as elastin degradation, vascular smooth muscle cell (VSMC) loss, and macrophage content at day 14 postelastase perfusion compared with control mice. The underlying mechanism(s) of the protective effect of MCP was associated with a decrease in galectin-3 and cytokine (mainly CCL5) mRNA and protein expression. Interestingly, galectin-3 induced CCL5 expression by a mechanism involving STAT3 activation in VSMC. Accordingly, MCP treatment decreased STAT3 phosphorylation in elastase-induced AAA. In conclusion, increased galectin-3 levels are associated with AAA progression, while galectin-3 inhibition decreased experimental AAA development. Our data suggest the potential role of galectin-3 as a therapeutic target in AAA.


Subject(s)
Aorta, Abdominal/drug effects , Aortic Aneurysm, Abdominal/prevention & control , Galectin 3/antagonists & inhibitors , Galectin 3/blood , Pancreatic Elastase , Pectins/pharmacology , Animals , Aorta, Abdominal/enzymology , Aorta, Abdominal/pathology , Aortic Aneurysm, Abdominal/blood , Aortic Aneurysm, Abdominal/enzymology , Aortic Aneurysm, Abdominal/pathology , Blood Proteins , Case-Control Studies , Cells, Cultured , Chemokine CCL5/genetics , Chemokine CCL5/metabolism , Dilatation, Pathologic , Disease Models, Animal , Disease Progression , Galectin 3/genetics , Galectin 3/metabolism , Galectins , Humans , Mice, Inbred C57BL , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/metabolism , Phosphorylation , RNA, Messenger/blood , RNA, Messenger/genetics , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Time Factors , Up-Regulation
13.
Nutrients ; 9(10)2017 Oct 24.
Article in English | MEDLINE | ID: mdl-29064409

ABSTRACT

Although there is accumulating evidence for a protective role of n-3 polyunsaturated fatty acids (n-3 PUFAs) on bone health, there are limited studies that examine the effect of altering dietary n-6:n-3 PUFA ratio with plant and marine sources of n-3 PUFA on bone health. Healthy adults (n = 24) were randomized into an eight-week crossover study with a four-week washout between treatments, with each subject consuming three of four diets. The four diets differed in the dietary n-6:n-3 PUFA ratios and either had an algal oil supplement added or not: (Control diet (10:1); α-linolenic acid (ALA) diet (2:1); Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) diet (10:1 plus supplement (S) containing EPA/DHA; Combination diet (2:1 + S)). The supplement was microalgae oil that provided 1 g EPA + DHA/day. Flaxseed oil and walnuts provided 8.6 g of ALA/day in the 2:1 diets. Serum levels of c-telopeptide (CTX), procollagen Type I N-terminal peptide, and osteocalcin showed significant correlation with age but none of the bone markers or peroxisomal proliferator-activated receptor-γ mRNA expression was significantly different between the diets. Serum CTX was negatively associated with red blood cell membrane linoleic acid and ALA and positively associated with membrane DHA. Neither altering dietary n-6:n-3 PUFA ratio from a 10:1 to a 2:1 ratio nor adding EPA/DHA supplement significantly changed bone turnover in the short term in healthy adults.


Subject(s)
Bone Remodeling/drug effects , Diet , Fatty Acids, Omega-3/administration & dosage , Fatty Acids, Omega-6/administration & dosage , Adult , Biomarkers , Collagen Type I/blood , Cross-Over Studies , Dietary Supplements , Female , Fish Oils/administration & dosage , Humans , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor I/metabolism , Male , Middle Aged , Nutrition Assessment , Osteocalcin/blood , PPAR gamma/blood , PPAR gamma/genetics , Patient Compliance , Peptide Fragments/blood , Peptides/blood , Plant Oils/administration & dosage , Procollagen/blood , RNA, Messenger/blood , RNA, Messenger/genetics , Single-Blind Method
14.
BMC Microbiol ; 17(1): 204, 2017 Sep 22.
Article in English | MEDLINE | ID: mdl-28938872

ABSTRACT

BACKGROUND: Dysbiosis of gut microbiota are commonly reported in autism spectrum disorder (ASD) and may contribute to behavioral impairment. Vitamin A (VA) plays a role in regulation of gut microbiota. This study was performed to investigate the role of VA in the changes of gut microbiota and changes of autism functions in children with ASD. RESULTS: Sixty four, aged 1 to 8 years old children with ASD completed a 6-month follow-up study with VA intervention. High-performance liquid chromatography was used to assess plasma retinol levels. The Autism Behaviour Checklist (ABC), Childhood Autism Rating Scale (CARS) and Social Responsiveness Scale (SRS) were used to assess autism symptoms. CD38 and acid-related orphan receptor alpha (RORA) mRNA levels were used to assess autism-related biochemical indicators' changes. Evaluations of plasma retinol, ABC, CARS, SRS, CD38 and RORA mRNA levels were performed before and after 6 months of intervention in the 64 children. Illumina MiSeq for 16S rRNA genes was used to compare the differences in gut microbiota before and after 6 months of treatment in the subset 20 of the 64 children. After 6 months of intervention, plasma retinol, CD38 and RORA mRNA levels significantly increased (all P < 0.05); the scores of ABC, CARS and SRS scales showed no significant differences (all P > 0.05) in the 64 children. Meanwhile, the proportion of Bacteroidetes/Bacteroidales significantly increased and the proportion of Bifidobacterium significantly decreased in the subgroup of 20 (all false discovery rate (FDR) q < 0.05). CONCLUSIONS: Bacteroidetes/Bacteroidales were the key taxa related to VA. Moreover, VA played a role in the changes in autism biomarkers. It remains unclear whether the VA concentration is associated with autism symptoms. TRIAL REGISTRATION: The study protocol was peer reviewed and approved by the institutional review board of Children's Hospital, Chongqing Medical University in 2013 and retrospectively registered in Chinese Clinical Trial Registry (ChiCTR) on November 6, 2014 (TRN: ChiCTR-ROC-14005442 ).


Subject(s)
Autism Spectrum Disorder/complications , Autism Spectrum Disorder/drug therapy , Dietary Supplements , Gastrointestinal Microbiome/drug effects , Vitamin A/pharmacology , ADP-ribosyl Cyclase 1/blood , Autism Spectrum Disorder/blood , Autism Spectrum Disorder/psychology , Biomarkers/blood , Child , Child Behavior/drug effects , Child, Preschool , DNA, Bacterial/analysis , Feces/microbiology , Female , Follow-Up Studies , Gastrointestinal Microbiome/genetics , Humans , Infant , Male , Non-Randomized Controlled Trials as Topic , Pilot Projects , RNA, Messenger/blood , RNA, Ribosomal, 16S/genetics , Single-Blind Method , Vitamin A/blood
15.
Thromb Haemost ; 117(7): 1402-1411, 2017 06 28.
Article in English | MEDLINE | ID: mdl-28382373

ABSTRACT

The system L neutral amino acid transporter (LAT; LAT1, LAT2, LAT3, or LAT4) has multiple functions in human biology, including the cellular import of S-nitrosothiols (SNOs), biologically active derivatives of nitric oxide (NO). SNO formation by haemoglobin within red blood cells (RBC) has been studied, but the conduit whereby a SNO leaves the RBC remains unidentified. Here we hypothesised that SNO export by RBCs may also depend on LAT activity, and investigated the role of RBC LAT in modulating SNO-sensitive RBC-endothelial cell (EC) adhesion. We used multiple pharmacologic inhibitors of LAT in vitro and in vivo to test the role of LAT in SNO export from RBCs and in thereby modulating RBC-EC adhesion. Inhibition of human RBC LAT by type-1-specific or nonspecific LAT antagonists increased RBC-endothelial adhesivity in vitro, and LAT inhibitors tended to increase post-transfusion RBC sequestration in the lung and decreased oxygenation in vivo. A LAT1-specific inhibitor attenuated SNO export from RBCs, and we demonstrated LAT1 in RBC membranes and LAT1 mRNA in reticulocytes. The proadhesive effects of inhibiting LAT1 could be overcome by supplemental L-CSNO (S-nitroso-L-cysteine), but not D-CSNO or L-Cys, and suggest a basal anti-adhesive role for stereospecific intercellular SNO transport. This study reveals for the first time a novel role of LAT1 in the export of SNOs from RBCs to prevent their adhesion to ECs. The findings have implications for the mechanisms of intercellular SNO signalling, and for thrombosis, sickle cell disease, and post-storage RBC transfusion, when RBC adhesivity is increased.


Subject(s)
Amino Acid Transport System L/antagonists & inhibitors , Amino Acid Transport System L/blood , Endothelial Cells/physiology , Erythrocytes/drug effects , Erythrocytes/physiology , Amino Acid Transport System L/genetics , Amino Acids, Cyclic/pharmacology , Animals , Benzoxazoles/pharmacology , Cell Adhesion/drug effects , Cell Adhesion/physiology , Cysteine/analogs & derivatives , Cysteine/pharmacology , Endothelial Cells/drug effects , Erythrocyte Deformability/drug effects , Erythrocyte Deformability/physiology , Human Umbilical Vein Endothelial Cells , Humans , In Vitro Techniques , Leucine/pharmacology , Mice , Mice, Nude , RNA, Messenger/blood , RNA, Messenger/genetics , Reticulocytes/physiology , S-Nitrosothiols/blood , S-Nitrosothiols/pharmacology , Tyrosine/analogs & derivatives , Tyrosine/pharmacology
16.
Ann Agric Environ Med ; 24(1): 104-107, 2017 Mar 21.
Article in English | MEDLINE | ID: mdl-28378983

ABSTRACT

INTRODUCTION AND OBJECTIVE: Heat stress induces the expression of genes encoding heat-shock proteins and immune response mediators. The aim of this study was to determine the differences in the expression of genes encoding heat-shock proteins 70 kDa and27 kDa, interleukin 6, interleukin 10and C-reactive protein, between athletes and non-athletes after sauna bathing. MATERIALS AND METHOD: Athletes (n=9) and non-athletes (n=9) were exposed to a Finnish sauna twice during one session at a temperature of 98.2 °C and humidity of 10% ± 2%, with a 5 min break for cooling down under a shower. The groups did not differ in terms of age, height or body mass. Blood samples were taken before and after sauna exposure in order to assess gene expression, using reverse transcription polymerase chain reaction. RESULTS: Differences were observed in leukocyte mRNA levels of tested genes between athletes and non-athletes. In the non-athlete group, all the tested genes were expressed at higher levels as a response to the same heat challenge. CONCLUSION: It appears that expression of stress-related genes induced by heat stress is dependent on the level of physical activity.


Subject(s)
Athletes , Heat-Shock Response/genetics , Leukocytes/metabolism , Steam Bath , C-Reactive Protein/genetics , C-Reactive Protein/metabolism , Gene Expression , HSP27 Heat-Shock Proteins/genetics , HSP27 Heat-Shock Proteins/metabolism , HSP70 Heat-Shock Proteins/genetics , HSP70 Heat-Shock Proteins/metabolism , Hot Temperature , Humans , Humidity , Interleukin-10/genetics , Interleukin-10/metabolism , Interleukin-6/genetics , Interleukin-6/metabolism , Male , RNA, Messenger/blood , Young Adult
17.
Invest New Drugs ; 35(3): 324-333, 2017 06.
Article in English | MEDLINE | ID: mdl-28150073

ABSTRACT

Introduction This was an open-label, dose escalation (3 + 3 design), Phase I study of SOR-C13 in patients with advanced tumors of epithelial origin. Primary objectives were to assess safety/tolerability and pharmacokinetics. Secondary goals were to assess pharmacodynamics and efficacy of SOR-C13. Methods SOR-C13 was administered IV QD on days 1-3 and 8-10 of a 21-day cycle. Doses were 2.75 and 5.5 mg/kg (20-min infusion) and 1.375, 2.75, 4.13 and 6.2 mg/kg (90-min infusion). Toxicity was assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Dose limiting toxicity (DLT) was assessed within the first treatment cycle. Tumors were evaluated, using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, after two cycles. Results Twenty-three patients were treated. No drug-related serious adverse events occurred. DLTs occurred in six patients: asymptomatic, drug-related, transient Grade 2 hypocalcemia (4 patients), and unrelated Grade 3 anemia and Grade 3 atrial fibrillation, 1 patient each. Calcium and vitamin D supplementation eliminated further Grade 2 hypocalcemia. One Grade 3 treatment emergent adverse event, urticaria, was definitely related to SOR-C13. Four possibly drug-related, Grade 3 events (alanine aminotransferase and aspartate aminotransferase elevation, headache, and hypokalemia) were observed. Of 22 evaluable patients, 54.5% showed stable disease ranging from 2.8 to 12.5 months. The best response was a 27% reduction in a pancreatic tumor with a 55% reduction in CA19-9 levels at 6.2 mg/kg. Conclusion SOR-C13 was safe and tolerated up to 6.2 mg/kg. The Maximal Tolerated Dose (MTD) was not established. Stable disease suggested antitumor activity.


Subject(s)
Antineoplastic Agents , Calcium Channel Blockers , Neoplasms/drug therapy , TRPV Cation Channels/antagonists & inhibitors , Adult , Aged , Alanine Transaminase/blood , Antineoplastic Agents/adverse effects , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Aspartate Aminotransferases/blood , Calcium Channel Blockers/adverse effects , Calcium Channel Blockers/pharmacokinetics , Calcium Channel Blockers/pharmacology , Calcium Channel Blockers/therapeutic use , Calcium Channels/genetics , Female , Headache/chemically induced , Humans , Hypocalcemia/chemically induced , Hypokalemia/chemically induced , Keratin-18/blood , Male , Maximum Tolerated Dose , Middle Aged , Neoplasms/metabolism , Peptides/adverse effects , Peptides/pharmacokinetics , Peptides/pharmacology , Peptides/therapeutic use , RNA, Messenger/blood , TRPV Cation Channels/adverse effects , TRPV Cation Channels/genetics , TRPV Cation Channels/pharmacokinetics , TRPV Cation Channels/pharmacology , TRPV Cation Channels/therapeutic use , Treatment Outcome , Urticaria/chemically induced
18.
Zhonghua Nan Ke Xue ; 23(12): 1063-1068, 2017 Dec.
Article in Chinese | MEDLINE | ID: mdl-29738174

ABSTRACT

OBJECTIVE: To induce hypospadias in male rat offspring by maternal exposure to di-n-butyl phthalate (DBP) during late pregnancy and further investigate its mechanisms. METHODS: We randomly divided 20 pregnant rats into a DBP exposure and a control group, the former treated intragastrically with DBP while the latter with soybean oil at 750 mg per kilogram of the body weight per day from gestation days (GD) 14 to 18. On postnatal day (PND) 1, we recorded the incidence rate of hypospadias and observed the histopathological changes in the genital tubercle of the hypospadiac rats. We also measured the level of serum testosterone (T) by radioimmunoassay and determined the mRNA and protein expressions of the androgen receptor (AR), sonic hedgehog (Shh), bone morphogenetic protein 4 (Bmp4) and fibroblast growth factor 8 (Fgf8) in the genital tubercle by real-time PCR and Western blot. RESULTS: No hypospadiac male rats were found in the control group. The incidence rate of hypospadias in male offspring was 43.6% in the DBP-treatment group. Histological analysis confirmed hypospadiac malformation. The serum testosterone concentration was decreased in the hypospadiac male rats as compared with the controls (ï¼»0.49 ± 0.05ï¼½ vs ï¼»1.12 ± 0.05ï¼½ ng/ml, P <0.05). The mRNA expressions of AR, Shh, Bmp4 and Fgf8 in the genital tubercle were significantly lower in the hypospadiac male rats than in the controls (AR: 0.50 ± 0.05 vs 1.00 ± 0.12, P <0.05; Shh: 0.65 ± 0.07 vs 1.00 ± 0.15, P <0.05; Bmp4: 0.42 ± 0.05 vs 1.00 ± 0.13, P <0.05; Fgf8: 0.46 ± 0.04 vs 1.00 ± 0.12, P <0.05), and so were their protein expressions (AR: 0.34 ± 0.05 vs 1.00 ± 0.09, P <0.05; Shh: 0.51 ± 0.07 vs 1.00 ± 0.12, P <0.05; Bmp4: 0.43 ± 0.05 vs 1.00 ± 0.11, P <0.05; Fgf8: 0.57 ± 0.04 vs 1.00 ± 0.13, P <0.05). CONCLUSIONS: Maternal exposure to DBP during late pregnancy can induce hypospadias in the male rat offspring. DBP affects the development of the genital tubercle by reducing the serum T concentration and expressions of AR, Shh, Bmp4 and Fgf8 in the genital tubercle, which might underlie the mechanism of DBP inducing hypospadias.


Subject(s)
Dibutyl Phthalate/toxicity , Hypospadias/chemically induced , Maternal Exposure , Plasticizers/toxicity , Animals , Body Weight , Bone Morphogenetic Protein 4/blood , Female , Fibroblast Growth Factor 8/blood , Hedgehog Proteins/blood , Hypospadias/blood , Hypospadias/pathology , Male , Pregnancy , RNA, Messenger/blood , Random Allocation , Rats , Rats, Sprague-Dawley , Receptors, Androgen/blood , Soybean Oil , Testosterone/blood
19.
Nutrients ; 8(12)2016 Dec 13.
Article in English | MEDLINE | ID: mdl-27983572

ABSTRACT

The aim of the study was to evaluate the effect of selenium supplementation on the expression of genes associated with glucose metabolism in humans, in order to explain the unclear relationship between selenium and the risk of diabetes. For gene expression analysis we used archival samples of cDNA from 76 non-diabetic subjects supplemented with selenium in the previous study. The supplementation period was six weeks and the daily dose of selenium was 200 µg (as selenium yeast). Blood for mRNA isolation was collected at four time points: before supplementation, after two and four weeks of supplementation, and after four weeks of washout. The analysis included 15 genes encoding selected proteins involved in insulin signaling and glucose metabolism. In addition, HbA1c and fasting plasma glucose were measured at three and four time points, respectively. Selenium supplementation was associated with a significantly decreased level of HbA1c but not fasting plasma glucose (FPG) and significant down-regulation of seven genes: INSR, ADIPOR1, LDHA, PDHA, PDHB, MYC, and HIF1AN. These results suggest that selenium may affect glycemic control at different levels of regulation, linked to insulin signaling, glycolysis, and pyruvate metabolism. Further research is needed to investigate mechanisms of such transcriptional regulation and its potential implication in direct metabolic effects.


Subject(s)
Blood Glucose/drug effects , Blood Glucose/genetics , Gene Expression Regulation/drug effects , Selenium/pharmacology , Trace Elements/pharmacology , Adult , Antigens, CD/blood , Antigens, CD/metabolism , Blood Glucose/metabolism , Dietary Supplements , Down-Regulation/drug effects , Fasting/blood , Female , Genes, myc/drug effects , Glycated Hemoglobin/analysis , Glycated Hemoglobin/drug effects , Homeostasis , Humans , Lactate Dehydrogenases/blood , Lactate Dehydrogenases/metabolism , Male , Mixed Function Oxygenases/blood , Mixed Function Oxygenases/metabolism , Pyruvate Dehydrogenase (Lipoamide)/blood , Pyruvate Dehydrogenase (Lipoamide)/metabolism , RNA, Messenger/blood , RNA, Messenger/isolation & purification , Receptor, Insulin/blood , Receptor, Insulin/metabolism , Receptors, Adiponectin/blood , Receptors, Adiponectin/metabolism , Repressor Proteins/blood , Repressor Proteins/metabolism , Selenium/administration & dosage , Trace Elements/administration & dosage
20.
Asia Pac J Clin Nutr ; 25(4): 747-753, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27702717

ABSTRACT

BACKGROUND AND OBJECTIVES: Peroral supplementation with trivalent-chromium (Cr) or magnesium (Mg) has been shown to improve insulin resistance (IR). The objective of this study was to determine whether combined peroral supplementation with Cr and Mg improves IR more effectively than Cr or Mg alone. METHODS AND STUDY DESIGN: Subjects (n=120, age range 45-59 years old) and diagnosed with IR were randomly divided into four groups and monitored for a period of 3 months: group 1 (the placebo control group), group 2 (160 µg/d Cr), group 3 (200 mg/d Mg), and group 4 (160 µg/d Cr plus 200 mg/d Mg). Fasting blood glucose (FBG), fasting insulin (FIns), erythrocyte Cr and Mg content, and glucose-transporter-4 (GLUT4) and glycogen-synthase-kinase-3ß (GSK3ß) mRNA levels in activated T-lymphocytes were measured, and insulin resistant index (IRI) was calculated. RESULTS: Significant decreases between the baseline and study conclusion values of FBG (0.37 mmol/L, p<0.01), FIns (2.91 µIU/mL, p<0.01) and IRI (0.60, p<0.01) were observed in group 4, but not groups 1-3. Similarly, compared with baseline, significant changes in GLUT4 (2.9-fold increase, p<0.05) and GSK3ß (2.2-fold decrease, p<0.05) mRNA levels in activated T-lymphocyte were observed at the study's conclusion in group 4, but not in groups 1-3. CONCLUSIONS: Our results indicate that combining peroral supplementation with Cr and Mg improves IR more effectively than Cr or Mg alone, and this may be attributable to increased induction and repression, respectively, of GLUT4 and GSK3ß expression.


Subject(s)
Chromium/administration & dosage , Insulin Resistance , Magnesium/administration & dosage , Blood Glucose/analysis , Chromium/blood , Dietary Supplements , Drug Therapy, Combination , Erythrocytes/chemistry , Fasting , Glucose Transporter Type 4/genetics , Glycogen Synthase Kinase 3 beta/genetics , Humans , Insulin/blood , Magnesium/blood , Middle Aged , RNA, Messenger/blood , T-Lymphocytes/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL